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In a prospective study, 139 serial blood samples from 15 transplant recipients were assessed for the presence
of cytomegalovirus (CMV) by virus isolation (CMV viremia) and by direct staining ofCMV antigens (CMV Ag)
in blood leukocytes (CMV antigenemia). CMV was isolated from 23 samples, whereas CMV Ag was detected
in 44 specimens. All positive samples were from a total of nine patients who were diagnosed as having active
CMV infections. In seven patients, active CMV infections were diagnosed by virus isolation from blood and
urine and by a significant rise of CMV-specific antibodies. In these patients, 21 of the 23 blood samples which
were positive for CMV by cell culture were also positive by direct CMV Ag detection. Moreover, CMV Ag were
detected in 23 of the 116 culture-negative samples. Twenty of these samples were from the acute phase of
infection in the same seven patients. The remaining three CMV Ag-positive specimens were from the other two
patients, from whom CMV was not isolated but who had serological evidence of concomitant active CMV
infections. These results suggest that direct detection of CMV Ag in peripheral blood leukocytes is as specific
as and more sensitive than current isolation techniques. Furthermore, by its sensitivity and inherent rapidity
the antigen detection test proved to be the earliest diagnostic marker of active CMV infection in eight of the nine
patients. Finally, it was shown that monoclonal antibodies to CMV immediate early antigens are a prerequisite
for demonstration of CMV antigenemia.
Active cytomegalovirus (CMV) infection is a major threat
in newborns (1) and immunocompromised individuals, such
as transplant recipients (12, 15) and patients with acquired
immunodeficiency syndrome (10). Rapid diagnosis of active
CMV infection is of great importance to avoid overtreatment
with immunosuppressive drugs (in transplant recipients) and
to guide antiviral therapy. For these reasons, rapid and
sensitive virus detection methods have been developed,
such as DNA probe techniques (21), CMV antigen (CMV
Ag) detection in biopsies and bronchoalveolar lavage (4, 8,
11), and immunofluorescence (IF) techniques for rapid de-
tection of CMV early antigens (EA) in cell culture within a
few days after inoculation of clinical specimens (6, 7, 11, 14,
19, 20, 22).
Demonstration of CMV in blood samples is particularly
important because CMV viremia is considered to be a
marker of active infection and has been shown to correlate
well with significant CMV disease (5, 18). Consequently,
assays aiming at rapid detection of CMV viremia are clini-
cally relevant. Large-scale studies on the detection of infec-
tious CMV in blood by the early antigen IF technique (19,
22) showed its usefulness as a more rapid and sensitive
method than the time-consuming conventional culture sys-
tem.
In a recent report (24), we have described a method for the
detection of CMV Ag in blood leukocytes (CMV antigene-
mia) with the aid of a mixture of monoclonal antibodies
(MAbs) C-10, C-11, and C-12. In the present study, we
focused on a comparison between virus isolation from and
CMV Ag detection in blood specimens with respect to
sensitivity and rapidity in 15 patients at risk for active CMV
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infection. In another comparative experiment, the useful-
ness of other MAbs for the demonstration of CMV antige-
nemia was studied.
MATERIALS AND METHODS
Clinical specimens. A total of 139 blood samples from 15
consecutive transplant recipients (11 renal, 2 hepatic, and 2
cardiac transplant patients) were studied prospectively for
the presence of CMV viremia and CMV antigenemia during
the first 3 months after transplantation. Samples were ob-
tained from the same venipuncture and processed indepen-
dently for virus isolation and antigen detection. Further-
more, urine specimens were tested for CMV, and sera were
tested for CMV-specific antibodies. Samples for all diagnos-
tic procedures were obtained weekly during the inpatient
period and subsequent outpatient visits and, for most pa-
tients, every 2 weeks during the last weeks of the 3-month
period. Active CMV infection was diagnosed by virus isola-
tion from the blood (by one or both assays mentioned below)
or a significant rise of CMV-specific antibodies (or both).
CMV syndromes (2) were defined as these laboratory criteria
combined with the occurrence of two or more of the follow-
ing CMV-related manifestations: unexplained fever for 2 or
more days, arthralgia, leukopenia (a leukocyte count of <3
x 109/liter) or thrombocytopenia (a platelet count of <100 x
109/liter), and liver enzyme rises (serum alanine aminotrans-
ferase activity of >50 U/ml).
MAbs. Three murine MAbs C-10, C-11, and C-12, have
been prepared in our laboratory. These are antibodies to
CMV immediate EA (IEA) (16) of 70 kilodaltons and react
with CMV-infected fibroblasts throughout the infectious
cycle and with the classical inclusion-bearing cytomegalic
cells in organs with disseminated CMV. No positive reaction
has been found in uninfected fibroblasts, herpes simplex
virus type 1-infected Vero cells, herpes simplex virus type 2-
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or varicella-zoster virus-infected fetal fibroblasts, or lym-
phoblastoid cell lines that express Epstein-Barr nuclear
(Raji) or virus capsid (P3HR1) antigens.
CMV viremia. For detection of infectious CMV in blood,
both conventional cell culture and detection of CMV Ag in
cell culture by IF were performed as previously described
(19). Briefly, buffy coats from 7 ml of heparinized blood were
obtained by dextransedimentation, and the cells were
washed twice and suspended in 1.5 ml of culture medium
(Hanks minimal essential medium supplemented with non-
essential amino acids, vitamins, and 10% fetal bovine
serum). For conventional cell culture, human embryonic
lung fibroblasts were grown in standard culture tubes, inoc-
ulated in duplicate with 0.5-ml portions of the buffy-coat
suspension, and placed at 36°C. On the next day, inoculum
cells were replaced by fresh culture medium. Subsequent
refreshments were done weekly. The fibroblast monolayers
were examined for a CMV-specific cytopathic effect three
times weekly during the first 2 weeks and weekly during the
next 4 weeks. For detection of CMV Ag in cell culture by IF,
lung fibroblasts were grown on 12-mm-diameter round cover
slips in flat-bottom tubes and inoculated in duplicate with
0.2-ml portions of the suspension of buffy coat cells. Inocu-
lum cells were replaced by fresh culture medium on the next
day. At 4 to 6 days after inoculation, the cover slips were
washed twice in phosphate-buffered saline (PBS), dried,
fixed in acetone (-20°C), and attached to microscope slides.
The cover slips were stained by indirect IF with a mixture of
the CMV-specific MAbs (C-10, C-11, and C-12) and fluores-
cein isothiocyanate-labeled rabbit anti-mouse immunoglob-
ulins (Dako, Copenhagen, Denmark) as the second antibody.
Urine specimens (CMV viruria). Urine specimens diluted
with virus transport medium were inoculated in duplicate in
0.5-ml portions and processed for detection of CMV Ag by
IF (after incubation for 1 day and 3 to 7 days) and for
conventional cell culture.
CMV antigenemia. CMV Ag staining was performed as
follows (24). EDTA-treated blood (3 to 5 ml) was mixed with
a 5% solution of dextran (250 kilodaltons) in PBS at a 4:1
ratio and allowed to settle at 37°C. After 15 min, the entire
supernatant was harvested and centrifuged for 10 min at 300
x g. The pelleted cells were suspended in an NH4Cl solution
(NH4Cl [8.3 g/liter], KHCO3 [1.0 g/liter], EDTA [0.03 g/
liter], pH 7.4) on iced water for 5 min to lyse the contami-
nating erythrocytes. After being washed twice in PBS, the
erythrocytes were suspended in PBS and counted. Cytocen-
trifuge preparations were made with 100 ,ul of a suspension
of 1.5 x 106 cells per ml centrifuged for 5 min at 600 to 800
rpm (Cytospin-2; Shandon-Elliot, Astmoor, United King-
dom). The slides were dried quickly with a cold blower and
fixed with acetone (10 min at room temperature). The slides
were then incubated in triplicate with 25 pi of a 1:10 diluted
mixture of MAbs C-10, C-11, and C-12 or with PBS (as a
negative control) for 30 min at room temperature. Subse-
quently, after being washed in PBS for 5 min, the slides were
incubated with horseradish peroxidase-labeled rabbit anti-
mouse immunoglobulin (Dako) diluted 1:20 with PBS with
1% human serum for 30 min room temperature. After being
washed three times in PBS, the enzyme reaction was per-
formed with a 3-amino-9-ethylcarbazole solution in 0.1 M
acetate buffer (pH 4.9) for 10 min at room temperature (10
mg of 3-amino-9-ethylcarbazole [Sigma Chemical Co., St.
Louis, Mo.; no. 5754] dissolved in 2.5 m of N,N-dimethyl-
formamide and then filled up to 50 ml with acetate buffer,
subsequently filtered, and supplemented with 50 itl of H202
[30%] per 50 ml of acetate buffer immediately before use).
FIG. 1. Two CMV Ag' blood leukocytes (arrows) showing ho-
mogeneous nuclear staining.
The slides were then washed with acetate buffer for S min,
rinsed with distilled water, mildly counterstained with he-
matoxylin (for about 1 min), carefully rinsed with tap water
to remove excess staining solution, and mounted in glycerol-
gelatin. Preparations known to contain CMV Ag' cells were
used as positive controls. CMV Ag' cells were identified by
characteristic (peri)nuclear staining (Fig. 1 and 2), mainly of
polymorphonuclear leukocytes (24). The presence of endog-
enous peroxidase activity (in the cytoplasm of eosinophilic
granulocytes [Fig. 2]) was generally a minor problem, largely
depending on a correct pH (4.9) of the 3-amino-9-ethylcar-
bazole buffer. When still necessary, endogenous peroxidase
activity can be eliminated by treatment of the slides with
glucose-glucose oxidase (9) or H202-methanol after incuba-
tion and subsequent formaldehyde fixation of the MAb
mixture (N. M. Jiwa, F. M. Van de Rijke, A. Molder, W.
Van der Bij, T. H. The, P. H. Rothbarth, J. Velsing, M. Van
der Ploeg, and A. K. Raap, submitted for publication).
In an additional experiment, the following CMV-specific
MAbs (see Table 4) were also tested for the ability to detect
CMV antigenemia: C-10, C-11, C-12, C-30, and C-32 (all
produced in our laboratory; obtainable from MCA Develop-
e
FIG. 2. Two CMV Ag' blood leukocytes (arrows) in which
staining is most intense on the margin of the nucleus (perinuclear
staining). e, Endogenous peroxidase activity.
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TABLE 1. Detection of CMV by cell culture (CMV viremia)
and CMV antigen detection in cytocentrifuged blood leukocytes
(CMV antigenemia)




High (>10)a 15 6
Low (.10)a 6 17
Negative 2 93
a Total number of CMV Ag' cells of triplicate cytospins.
ment BV, Groningen, The Netherlands), MAB810 (pur-
chased from Chemicon, El Segundo, Calif.), 95/30 (kindly
provided by S. Michelson, Paris, France), HCMV3 and
HCMV19 (purchased from Bioscot, Edinburgh, United
Kingdom), and MAb anti-EA (product 9121, purchased from
Biotech, Rockville, Md.). Cytospin slides with high numbers
of CMV Ag' cells (ranging from 30 to >1,000 positive cells
per slide) were selected for staining with these MAbs. These
slides were from nine patients (one newborn, four renal
transplant recipients, one cardiac transplant recipient, one
hepatic transplant recipient, and two patients with Wege-
ner's granulomatosis) with virologically and serologically
proven active CMV infections. Optimal dilutions (see Table
4) of the MAbs used were determined by application to
AD169-infected human embryonic fibroblasts and CMV Ag'
slides.
CMV serology. Levels of CMV-specific immunoglobulin G
(IgG) and IgM antibodies were measured in duplicate by an
enzyme-linked immunosorbent assay (13). Extinctions of a
sample at several dilutions were compared with those of a
referenice serum pool. The antibody levels were expressed as
percentages of that pool. Seroconversion or an increase of
antibody levels exceeding the level of the previous serum by
at least three times the standard deviation of that measure-
ment was considered significant.
RESULTS
We assessed 139 blood samples from 15 transplant recip-
ients prospectively for infectious CMV by cell culture (vi-
remia) and for the presence of CMV antigens in blood
leukocytes (antigenemia). CMV viremia was documented in
23 samples, and CMV antigenemia was found in 44 samples
(Table 1).
Active CMV infection was present in 9 of the 15 patients
(Table 2); 1 patient had a primary CMV infection, and 8 had
secondary CMV infections. Most patients had minor clinical
symptoms; a CMV syndrome occurred in two patients, but
the outcome of the disease appeared to be uncomplicated in
these patients. Active CMV infection was evidenced in
seven of the nine patients both by recovery of CMV from
blood and urine on one or more occasions and by a signifi-
cant CMV antibody rise. CMV viremia was demonstrated in
these patients by conventional cell culture or the IF assay for
early antigen detection (or both methods), yielding 23 posi-
tive samples. CMV Ag' leukocytes were detected in 21 of
these 23 samples. In addition, CMV Ag' leukocytes were
demonstrated in 20 culture-negative blood samples in these
seven patients. The remaining three CMV Ag-positive blood
cell preparations were from two asymptomatic patients,
from whom CMV could not be recovered but who displayed
a significant rise of CMV-specific antibodies within 2 weeks
after the CMV Ag' samples (patients 9 and 10). CMV Ag'
cells were not detected in two culture-positive samples and
in all samples of the remaining six transplant recipients
without active CMV infection.
Furthermore, we compared virus isolation from the buffy
coat and the cytospin technique with respect to the number
of CMV Ag' cells (Table 1). Virus isolation by cell culture
appeared to be associated with high numbers (>10 cells per
measurement) of CMV Ag' cells and vice versa (chi square
= 7.32, P < 0.01, df = 1).
CMV antigenemia could be demonstrated during a longer
period than CMV viremia (5 + 3 [mean + the standard
deviation] versus 3 2 weeks, respectively). This is illus-
TABLE 2. Patient data and diagnostic results
Patient Age Sex and
a CMV serostatus' CMV antigenemia CMV viremiae CMV viruriae CMV ELISAf CMV syndrome5
no. (yr) transplant typea Periodc Maximumd
1 50 F, H Seropositive 21-70 34 49 + 28 70 + 1 41 37-54
2 52 F, R Seropositive h
3 22 M, H Seronegative
4 60 F, R Seropositive 35-91 69 28 + 6 56 + 1 48
5 40 M, C Seropositive 19-82 72 34 + 6 34 + 1 41
6 25 F, R Seronegative
7 59 F, R Seronegative
8 48 M, R Seropositive
9 60 F, R Seropositive 32 1 38
10 63 M, R Seropositive 53-59 S - 66
il 52 F, R Seronegative
12 50 F, R Seropositive 25-46 40 32 + 6 52 + 1 37
13 46 M, R Seropositive 21-50 245 28 + 6 35 + 1 40
14 29 M, R Seropositive 28-55 242 49 + 6 35 + 7 40 38-52
15 31 M, C Seronegative 21-52 305 35 + 4 35 + 7 35
a F, Female; M, male. H, R, and C refer to hepatic, renal, and cardiac transplant recipients.
b Determined immediately before transplantation.
C Period (days) between first and last positive CMV Ag detections.
d Total number of CMV Ag' cells oi- triplicate cytospins of maximum measurement.
e First positive measurement (day of sampling plus days required for processing of the sample).
f Significant increase of CMV-specific IgG or IgM (or both) antibodies (number of days after transplantation). ELISA, Enzyme-linked immunosorbent assay.
9 Days after transplantation.
h
-, CMV not detected, no antibody rise, or no CMV syndrome.
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TABLE 3. Longitudinal course of CMV-related diagnostic
parameters in patient 13'
Wk after CMV CMV CMV CMV ELISAC
transplantation antigenemiab viremia viruria IgG IgM
1 - - - 55 <1
2 - - - 45 <1
3 1 - - 44 <1
4 98* + - 29 <1
5 245* + + 72 <1
6 29* - + -500 14
7 3 - + .1,000 10
8 - - + -1,300 10
9 - - + .1,100 12
10 - - + .1,300 18
12 - - +
a See the text for details. +, CMV detected; -, CMV not detected.
b Total number of CMV Ag+ cells of triplicate cytospins. *, Intermittent
fever from days 29 to 41 after renal transplantation.
c Antibody levels are expressed as percentages of that of a reference serum
pool. ELISA, Enzyme-linked immunosorbent assay.
trated by the longitudinal course of CMV viremia and CMV
antigenemia in patient 13 (Table 3). Regarding the rapidity of
the different methods, the following results were obtained.
Buffy-coat specimens were identified as positive by conven-
tional cell culture at a mean of 20 days (range, 7 to 42 days)
after inoculation. The time required for EA detection in cell
culture by IF averaged 4 to 6 days. The direct method of
CMV Ag detection in blood leukocyte preparations usually
yielded results within 3 to 5 h. The clinical relevance of these
findings is illustrated by a chronologic comparison of the
blood tests used for the nine patients with active CMV
infections. Table 2 presents the number of days after trans-
plantation when the first positive result was obtained by the
different diagnostic techniques. CMV antigenemia was diag-
nosed from -1 to 56 days before CMV was demonstrated by
cell culture of blood samples, from 8 to 50 days before virus
isolation from urine, and from 6 to 22 days before a signifi-
cant CMV antibody rise. Consequently, with one exception
(patient 4), CMV Ag-positive cells were detectable before
any other diagnostic result was obtained.
The ability of other MAbs (Table 4) to demonstrate CMV
antigenemia was studied by using a panel of slides with
TABLE 4. Usefulness of distinct CMV specific MAbs for
demonstration of CMV antigenemia in nine patients with active
CMV infections
Molecular No. of patients
MAb Specificitya mass Fluid and with CMV(kDa) antigenemia
C-10 IEA 70 Sup., 1:10 9
C-11 IEA 70 Sup., 1:10 9
C-12 IEA 70 Sup., 1:10 9
MAB810 IEA 68 Asc., 1:30 9
95/30 IEA 68 Asc., 1:100 9
HCMV19 IEA 66 Asc., 1:100 9
anti-EA EA NDC Asc., 1:50 2
HCMV3 EA ND Asc., 1:50 1
C-30 LA 60 Sup., undiluted 0
C-32 LA 53 Sup., undiluted 0
a CMV-IEA was defined as described by Reddehase and Koszinowski (16),
and CMV EA and LA were defined as described by The et al. (23).
b Sup., Hybridoma supernatant; Asc., murine ascites.
c ND, Not determined.
proven CMV Ag positivity. It was found that CMV antige-
nemia could be demonstrated in all cases provided that
MAbs to CMV IEA (16) were used. In our experience.
MAbs MAB810 and HCMV19 generally displayed a lower
staining intensity than did the other CMV IEA-specific
MAbs. CMV EA (23)-specific MAbs appeared to be positive
in a small number of the preparations, while CMV late
antigen (LA) (23)-specific MAbs were not reactive.
DISCUSSION
Isolation of CMV from blood specimens is considered to
be a marker of active, clinically important CMV infection.
However, because development of a cytopathic effect char-
acteristic for CMV in the conventional culture technique is
hampered by the slow replication of the virus, this method of
virus isolation is of only limited value for the clinical
management of immunocompromised patients. Recently,
the time required for demonstration of infectious CMV in
blood has been successfully reduced by using MAbs for
detection of CMV EA in cell culture (14, 19). In the present
study, we compared the detection of CMV in blood by cell
culture with detection by a blood test based on direct
detection of CMV antigens in blood leukocytes.
CMV Ag' blood leukocytes were detected in 44 samples,
of which tissue culture proved to be positive in 21 cases.
Twenty culture-negative samples were from seven patients
from whom CMV was isolated both by a previous or
subsequent blood sample by cell culture and by a urine
sample, together with a significant CMV antibody rise. The
remaining three samples were from two patients with sero-
logical evidence of active CMV infection. Thus, correct
demonstration of CMV by antigen staining in blood leuko-
cytes was supported by virus isolation from blood and urine
or by confirmative serological tests during the same period
(or by both methods). Since no CMV Ag' leukocytes were
detected in only two culture-positive samples and the virus
was not recovered by cell culture from 23 CMV Ag'
samples, it appears that the technical sensitivity (i.e., the
ability to detect CMV in CMV-positive blood samples) of
direct CMV Ag detection is superior to that of virus isolation
from blood. This is supported by the relationship between
numbers of Ag' cells and virus isolation (Table 1). This
higher sensitivity can be explained in a number of ways.
Since CMV isolation depends on infectious CMV and,
hence, on the functional integrity of the virus (and the
fibroblast monolayer), it can be reasoned that virus isolation
is sensitive to exterior influences, such as transport of the
sample and toxicity by disrupted blood leukocytes (14, 19).
This might explain the six culture-negative samples with high
numbers of CMV Ag' cells (Table 1). If a virus replicative
cycle is necessary for transfer of an infectious virus from
blood cells to the fibroblast monolayer, another factor could
be the abortive nature ofCMV infection of blood leukocytes,
as described for in vitro-infected blood leukocytes (3, 17)
and as suggested by the IEA+/EA+/LA- pattern of CMV-
infected blood cells in vivo (Table 4). However, it is not clear
whether antigen detection and virus isolation refer to the
same type of blood leukocyte.
From a practical point of view, the cytospin technique has
certain advantages over culture techniques. The test takes
just a few milliliters of blood, is easy to perform, needs no
culture facilities, and provides results with a negligible
delay. Because of their characteristic staining, (even low
numbers of) CMV Ag' cells are readily identifiable and
allow a correct diagnosis. In the present report, the use of
J. CLIN. MICROBIOL.
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MAbs to CMV IEA (16) is shown to be necessary for correct
demonstration of CMV antigenemia.
The combination of rapidity and sensitivity results in early
diagnosis (Tables 2 and 3) of active CMV infection (generally
1 week to several weeks before other diagnostic markers)
and makes the cytospin technique relevant for the clinical
management of immunosuppressed patients and for evalua-
tive studies on the efficacy of antiviral drugs. Regarding the
clinical sensitivity (i.e., the ability to diagnose an active
CMV infection), the present results (9 of 9 patients) are
comparable to those of a recent study (25 of 27 renal
transplant patients) (24).
In summary this study suggests that detection of CMV Ag
in blood leukocytes is as specific as and more rapid and
sensitive than the virus isolation assays commonly used for
demonstration of CMV in blood and thus for the diagnosis of
active CMV infections.
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